ICER to Review Five Biologic Drugs Used for Severe Asthma
The Institute for Clinical and Economic Review (ICER) is going to review the class of biologic drugs used to treat moderate to severe eosinophilic asthma and release a report in November, the organization said.
The Institute for Clinical and Economic Review (ICER) is going to review the class of biologic drugs used to treat moderate to severe eosinophilic asthma and release a report in November, the organization said.
The asthma drugs are:
- Dupilumab (Dupixent, Sanofi/Regeneron)
- Omalizumab (Xolair, Genentech/Novartis),
- Mepolizumab (Nucala, GlaxoSmithKline)
- Reslizumab (Cinqair, Teva)
- Benralizumab (Fasenra, AstraZeneca)
ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for
In its previous report on mepolizumab, ICER said the therapy should be priced far below its list price of $32,500 a year, suggesting that it would be cost effective if priced at no more than $7800 to about $12,000 a year.
Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in this October. It has “breakthrough” designation for its use in severe atopic dermatitis (AD) and is intended for patients whose condition has not improved with use of topical treatments, or who are not advised to take these treatments. Dupilumab works on 2 interleukins that are believed to trigger AD by binding to their cell receptors to calm the inflammatory response and reduce the symptoms.
Last year, ICER recommended that dupilumab represented a good value as it improved health outcomes even thought there were some additional costs.
Asthma costs the US economy more than $80 billion annually in medical expenses, days missed from work and school, and deaths, according to
An estimated 22 million Americans have asthma, and
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025